Amifampridine

4-Aminopyridine derivative that acts as a POTASSIUM CHANNEL blocker to increase release of ACETYLCHOLINE from nerve terminals. It is used in the treatment of CONGENITAL MYASTHENIC SYNDROMES.

Also Known As:

3,4-Diaminopyridine; Amifampridine Phosphate; Firdapse; 3,4 Diaminopyridine; Ruzurgi; 3,4-Pyridinediamine

Networked: 145 relevant articles (23 outcomes, 23 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Oh, Shin J: 6 articles (10/2021 - 11/2009)
2.	Mantegazza, Renato: 4 articles (01/2021 - 12/2015)
3.	Maggi, Lorenzo: 3 articles (11/2022 - 01/2018)
4.	Maddison, Paul: 3 articles (12/2012 - 02/2011)
5.	Moyer, Michelle: 3 articles (12/2008 - 01/2002)
6.	Bonanno, Silvia: 2 articles (11/2022 - 01/2018)
7.	Ingenito, Gary: 2 articles (11/2022 - 01/2021)
8.	Machamer, James B: 2 articles (01/2022 - 01/2018)
9.	McNutt, Patrick M: 2 articles (01/2022 - 01/2018)
10.	Matsushima, Masaaki: 2 articles (02/2018 - 08/2007)

Related Diseases

1.	Lambert-Eaton Myasthenic Syndrome (Lambert-Eaton Syndrome) 09/01/1998 - "3,4-Diaminopyridine (3,4-DAP) is known to be beneficial in the symptomatic treatment of the Lambert-Eaton myasthenic syndrome (LEMS). " 11/01/2009 - "The purpose of this study was to investigate the clinical and electrophysiological efficacy of 3,4-diaminopyridine (DAP) in patients with Lambert-Eaton myasthenic syndrome (LEMS) in a randomized, double-blind, cross-over drug trial. " 03/01/2019 - "To assess tolerability and efficacy of amifampridine phosphate versus placebo for symptomatic treatment of Lambert-Eaton Myasthenic Syndrome (LEMS). " 08/01/1998 - "Single-fiber electromyography improvement with 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome." 09/25/2021 - "3,4-diaminopyridine treatment for Lambert-Eaton myasthenic syndrome in adults: a meta-analysis of randomized controlled trials."
2.	Myasthenia Gravis 02/16/2011 - " trials of 3,4-diaminopyridine reported significant improvement in the primary outcome, muscle strength score, or myometric limb measurement for between hours and a week following treatment, and significant improvement in resting compound muscle action potential (CMAP) amplitude following 3,4-diaminopyridine, compared with placebo.A meta-analysis of the primary endpoint showed Quantitative Myasthenia Gravis (QMG) muscle score assessed between three and eight days was likely to improve by a mean of 2.44 points (95% confidence interval 3.6 to 1.22). " 01/01/1985 - "Improvement in neuromuscular transmission in myasthenia gravis by 3,4-diaminopyridine." 01/01/2022 - "Effects of 3,4-diaminopyridine on myasthenia gravis: Preliminary results of an open-label study." 01/01/2022 - "Objective: to assess 3,4-diaminopyridine (3,4-DAP) effects and tolerability in patients with anti-AChR myasthenia gravis. " 11/01/1996 - "Eleven patients with congenital and five with juvenile myasthenia gravis, aged 5 to 24 years, were given 3,4-diaminopyridine in a double-blind, placebo-controlled, crossover study. "
3.	Paralysis (Palsy) 06/30/1985 - "3,4-Diaminopyridine (3,4-DAP), a compound which increases nerve-evoked transmitter release by increasing Ca2+ influx, was more effective in reversing the paralysis in type A than in type F-treated muscles. " 01/01/1983 - "However, 3,4-diaminopyridine, an agent which increases nerve-evoked transmitter release by increasing Ca2+ influx, was more effective in reversing the paralysis in type A than in type B-treated muscles.(ABSTRACT TRUNCATED AT 250 WORDS)" 01/01/2018 - "3,4-diaminopyridine reverses paralysis in botulinum neurotoxin-intoxicated diaphragms through two functionally distinct mechanisms." 02/01/2001 - "Data suggesting that BoNT/E can enter BoNT/A-treated preparations was obtained by findings that 3,4-diaminopyridine, which readily reversed muscle paralysis after BoNT/A exposure, lost this ability within 1 h of BoNT/E addition. " 06/01/1986 - "3,4-Diaminopyridine was also evaluated for its ability to reverse the paralysis due to botulinum toxin. "
4.	Muscle Weakness 01/01/2009 - "He started taking 3,4-diaminopyridine and his muscle weakness improved dramatically, and he was eventually able to walk finally. " 01/01/2021 - "3,4-Diaminopyridine (3,4-DAP) and its phosphate form, 3,4-DAPP have been used efficiently in the past years to treat muscular weakness in myasthenic syndromes with neuromuscular junctions (NMJs) impairment. " 04/01/1995 - "Antagonism of botulinum toxin-induced muscle weakness by 3,4-diaminopyridine in rat phrenic nerve-hemidiaphragm preparations." 01/01/2020 - "Even under adequate therapy with pyridostigmine (PS) and 3,4-diaminopyridine, CHAT-mutations led to the progression of muscular weakness partly in combination with persistent respiratory and bulbar symptoms. " 05/15/2013 - "Muscle weakness can be improved upon treatment with pyridostigmine, a cholinesterase inhibitor, or with 3,4-diaminopyridine, which increases the release of ACh quanta. "
5.	Multiple Sclerosis 08/21/2002 - "The present study compares two methods of preparation of microparticles of 3,4-diaminopyridine (3,4-DAP) for the treatment for multiple sclerosis and Lambert-Eaton myasthenia syndrome. " 12/01/1996 - "To examine the efficacy and toxicity of oral 3,4 diaminopyridine (DAP) in dosages up to 100 mg/day, 36 patients with multiple sclerosis (MS) enrolled in a randomized, double-blind, placebo-controlled, crossover trial. " 12/01/1996 - "Treatment with oral 3,4 diaminopyridine improves leg strength in multiple sclerosis patients: results of a randomized, double-blind, placebo-controlled, crossover trial." 04/01/1990 - "Preliminary trial of 3,4-diaminopyridine in patients with multiple sclerosis." 05/01/1998 - "An open-labelled clinical and electrophysiological study of 3,4 diaminopyridine in the treatment of fatigue in multiple sclerosis."

Related Drugs and Biologics

1.	Intravenous Immunoglobulins (IVIG)
2.	Pyridostigmine Bromide (Pyridostigmine)
3.	Phosphotransferases (Kinase)
4.	4-Aminopyridine (4 Aminopyridine)
5.	Cholinesterase Inhibitors (Anticholinesterases)
6.	Phosphates (Orthophosphate)
7.	Botulinum Toxins (Botulinum Toxin)
8.	Potassium
9.	Intercellular Signaling Peptides and Proteins (Growth Factors)
10.	Brain-Derived Neurotrophic Factor (BDNF)

Related Therapies and Procedures

1.	Therapeutics
2.	Aftercare (After-Treatment)
3.	Immunomodulation
4.	Thymectomy
5.	Palliative Care (Palliative Therapy)